Publications by authors named "Xue-Ai Song"
Article Synopsis
- A new drug called Keguan-1 was developed to help manage acute respiratory distress syndrome (ARDS) in COVID-19 patients through a controlled clinical trial.
- The trial compared Keguan-1 combined with standard therapy against standard therapy alone, assessing outcomes like adverse events and time to fever resolution.
- Results indicated that the Keguan-1 group experienced a faster recovery from fever and a lower incidence of ARDS compared to the control group, confirming its safety and effectiveness.
The coronavirus disease 2019(COVID-19) is raging in China and more than 20 other countries and regions since the middle of December 2019. Currently, there is no specific drug or vaccine besides symptomatic supportive therapy. Taking full advantage of the clinical experience of traditional Chinese medicine(TCM) in preventing and controlling major epidemics such as SARS, it is an important mission for TCM to propose effective formula with immediate response and solid evidence by using modern biomedical knowledge and techniques(molecular docking assisted TCM formulation for short).
View Article and Find Full Text PDFObjectives: The present study aimed to evaluate the association between the concurrence of pre-existing chronic liver diseases (CLD) and worse prognosis in patients with HILI.
Design: A case-control study.
Setting: Tertiary hospital specialising in liver diseases in China.
Article Synopsis
- * A study of 161 individuals revealed that Ebola Virus Disease (EVD) survivors exhibited the highest psychological distress, followed by medical staff, logistics staff, medical students, and Chinese medical staff.
- * Five psychological symptoms were notably severe in EVD survivors, and higher education levels were linked to lower general severity index scores, highlighting the need for mental health considerations in emergency response plans for future outbreaks.
Article Synopsis
- The study analyzed data from 285 patients with confirmed Ebola virus disease (EVD) treated at Jui Government Hospital in Sierra Leone during the 2014-2015 outbreak, focusing on recovery and mortality rates.
- Out of the 285 patients, 146 recovered, leading to an overall survival rate of 51.23%, with very young children (under 6 years) having the lowest survival at 37.50%.
- Key factors that predicted poor outcomes included high blood viral load, confusion, abdominal pain, vomiting, and conjunctivitis, with most deaths occurring within the first week of hospitalization.